The efficacy and safety of 0.5% topical timolol on corneometry and transepidermal water loss after ablative fractional CO2 laser for atrophic acne scars: a split face randomized double blind placebo-controlled trial
Phase 3
Recruiting
- Conditions
- We considered that timolol may have an effect in wound healing promotion in patients who undergo AFCO2 resurfacing. Our study aimed to investigate the efficacy and safety of 0.5% topical timolol malea
- Registration Number
- TCTR20190722005
- Lead Sponsor
- none
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
The participants aged 18-50 years old with atrophic area scars for at least three months
Exclusion Criteria
1) pregnant/lactating female, 2) history of isotretinoin use within previous 3 months before enrollment, 3) history of cosmetic procedures including botulinum toxin, filler, collagen, lasers within the preceding 3 months, 4) history of photosensitivity or skin cancer, 5) history of psoriasis, hypertension, or asthma, 6) allergy to anesthetic agents, or timolol solution, 7) active dermatitis or herpes infection (within previous 2 weeks), 8) Fitzpatrick skin type V †VI, 9) current or history of previous use within one month of anticoagulative drugs or NSAIDs use or previous use
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method corneometry and TEWL - biophysical measurements by Cutometer dual MPA 580
- Secondary Outcome Measures
Name Time Method edema, erythema, and crusting score - 4-point grading scale by dermatologists